Compare AORT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | HCM |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1993 | N/A |
| Metric | AORT | HCM |
|---|---|---|
| Price | $43.48 | $16.03 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $49.36 | $13.75 |
| AVG Volume (30 Days) | ★ 304.0K | 59.0K |
| Earning Date | 02-23-2026 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $422,646,000.00 | ★ $602,197,000.00 |
| Revenue This Year | $15.97 | N/A |
| Revenue Next Year | $10.96 | $15.54 |
| P/E Ratio | ★ N/A | $5.89 |
| Revenue Growth | ★ 9.81 | N/A |
| 52 Week Low | $21.97 | $11.51 |
| 52 Week High | $48.25 | $19.50 |
| Indicator | AORT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 75.72 |
| Support Level | $41.82 | $14.63 |
| Resistance Level | $45.99 | $15.00 |
| Average True Range (ATR) | 1.38 | 0.42 |
| MACD | -0.28 | 0.26 |
| Stochastic Oscillator | 33.07 | 90.63 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.